E-LIB Suche - Ergebnisse für: Prabhu, Snehit

1

Risk Factors for Hematotoxicity Following Tisagenlecleucel ..:

McNerney, Kevin Owen ; Fabrizio, Vanessa A. ; Talleur, Aimee C....
Transplantation and Cellular Therapy. 30 (2024) 2 - p. S219-S220 , 2024

Link: https://doi.org/10.1016/..

2

Establishing Costs for Commercial Chimeric Antigen Receptor..:

Satwani, Prakash ; Chao, Karen ; Lopez-Garcia, Maria...
Transplantation and Cellular Therapy. 30 (2024) 2 - p. S224-S225 , 2024

Link: https://doi.org/10.1016/..

3

Mediport use as an acceptable standard for CAR T cell infus..:

Eylon, Maya ; Prabhu, Snehit ; John, Samuel...
Frontiers in Immunology. 14 (2023) - p. , 2023

Link: https://doi.org/10.3389/..

4

Higher doses of tisagenlecleucel are associated with improv..:

Stefanski, Heather E. ; Eaton, Anne ; Baggott, Christina...
Blood Advances. 7 (2023) 4 - p. 541-548 , 2023

Link: https://doi.org/10.1182/..

5

HLH-like toxicities predict poor survival after the use of ..:

McNerney, Kevin O. ; Si Lim, Stephanie J. ; Ishikawa, Kyle...
Blood Advances. 7 (2023) 12 - p. 2758-2771 , 2023

Link: https://doi.org/10.1182/..

6

Mediport Use As an Acceptable Standard for CAR T Cell Infus..:

Eylon, Maya ; Baggott, Christina ; Prabhu, Snehit...
Transplantation and Cellular Therapy. 29 (2023) 2 - p. S195-S196 , 2023

Link: https://doi.org/10.1016/..

7

Tisagenlecleucel utilisation and outcomes across refractory..:

Barsan, Valentin ; Li, Yimei ; Prabhu, Snehit...
eClinicalMedicine. 65 (2023) - p. 102268 , 2023

Link: https://doi.org/10.1016/..

8

High Disease Burden and Severe Neutropenia Predict HLH Toxi..:

McNerney, Kevin O. ; Lim, Stephanie Si ; Miller, Alexandra...
Transplantation and Cellular Therapy. 29 (2023) 2 - p. S202-S203 , 2023

Link: https://doi.org/10.1016/..

9

CAR-Associated Hemophagocytic Lymphohistiocytosis (HLH) wit..:

McNerney, Kevin O. ; Lim, Stephanie Si ; Dreyzin, Alexandra...
Transplantation and Cellular Therapy. 28 (2022) 3 - p. S473-S475 , 2022

Link: https://doi.org/10.1016/..

10

Tisagenlecleucel outcomes in relapsed/refractory extramedul..:

Fabrizio, Vanessa A. ; Phillips, Christine L. ; Lane, Adam...
Blood Advances. 6 (2022) 2 - p. 600-610 , 2022

Link: https://doi.org/10.1182/..

11

DIPG-15. Major tumor regressions in H3K27M-mutated diffuse ..:

Monje, Michelle ; Majzner, Robbie ; Mahdi, Jasia...
Neuro-Oncology. 24 (2022) Supplement_1 - p. i20-i21 , 2022

Link: https://doi.org/10.1093/..

12

Optimal fludarabine lymphodepletion is associated with impr..:

Fabrizio, Vanessa A. ; Boelens, Jaap Jan ; Mauguen, Audrey...
Blood Advances. 6 (2022) 7 - p. 1961-1968 , 2022

Link: https://doi.org/10.1182/..

13

Real-world use of tisagenlecleucel in infant acute lymphobl..:

Moskop, Amy ; Pommert, Lauren ; Baggott, Christina...
Blood Advances. 6 (2022) 14 - p. 4251-4255 , 2022

Link: https://doi.org/10.1182/..

14

Post-infusion CAR TReg cells identify patients resistant to..:

Good, Zinaida ; Spiegel, Jay Y. ; Sahaf, Bita...
Nature Medicine. 28 (2022) 9 - p. 1860-1871 , 2022

Link: https://doi.org/10.1038/..

15

Post-Relapse Outcomes Following Tisagenlecleucel: Poor Surv..:

Stefanski, Heather E ; Verneris, Michael R. ; Eaton, Anne...
Transplantation and Cellular Therapy. 27 (2021) 3 - p. S117-S118 , 2021

Link: https://doi.org/10.1016/..